|Bid||4.60 x 800|
|Ask||8.44 x 2200|
|Day's Range||7.53 - 7.78|
|52 Week Range||2.78 - 9.02|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 7, 2017 - Aug 11, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||12.33|
Following the recent announcement of positive field trial data in a European field trial, the Company met earlier today with investors and analysts at NASDAQ’s headquarters to provide an update on the progress towards the commercialization of MosaiQ. Information presented included a demonstration of the features of the MosaiQ instrument designed to bring automated high throughput microarray based diagnostic testing to transfusion diagnostics and beyond. Franz Walt, Quotient’s CEO, presented the Quotient strategy for MosaiQ and the unique opportunity in the large transfusion diagnostics market. In addition, a voice of customer video described that market’s urgent need for innovation. Jeremy Stackawitz, the Company’s President of Commercial, explained how MosaiQ’s unique product design is expected to meet the stated need of customers in an affordable automated format designed to deliver value through a reduction in the total cost of ownership when compared to currently available solutions.
Quotient Limited (QTNT), a commercial-stage diagnostics company (the Company), has completed the offering of up to $120.0 million aggregate principal amount of its 12% Senior Secured Notes due 2023 (the “Notes”). On June 29, 2018, the Company, completed the second and final closing (the “Second Closing”) of its offering of the Notes. Upon the Second Closing, the Company issued an additional $36.0 million aggregate principal amount of the Notes (the “Additional Notes”).
Stock Research Monitor: QTNT, ADMP, and PETS LONDON, UK / ACCESSWIRE / June 28, 2018 / If you want a free Stock Review on VRX sign up now at www.wallstequities.com/registration . On Wednesday, June 27, ...
Quotient Limited’s (NASDAQ:QTNT): Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and commercializes conventional reagent products used for blood grouping in the transfusion diagnostics market worldwide. The US$402.65m market-cap companyRead More...
JERSEY, Channel Islands, June 18, 2018-- Quotient Limited, a commercial-stage diagnostics company, today announced that it will host an Investor Day on Monday, July 16, 2018 from 9:00am– 1:00pm ET, in ...
Quotient Limited (QTNT), a commercial-stage diagnostics company, today reported concordance data for the initial MosaiQ blood grouping microarray generated in its European field trial, which exceed the targeted criteria for submission for CE marking. Under the terms of the indenture governing its 12% Senior Secured Notes due 2023, Quotient now plans to issue an additional $36 million of notes with funding to occur within 10 business days of the date of this press release. “It gives me great pleasure to report positive field trial results for our initial blood grouping microarray,” said Franz Walt, Chief Executive Officer of Quotient.
On a per-share basis, the Eysins, Jersey-based company said it had a loss of 44 cents. The blood test developer posted revenue of $6.1 million in the period. For the year, the company reported that its ...
MosaiQ European field trial which commenced on May 17, 2018 is ongoing Franz Walt is appointed as Chief Executive Officer Fourth quarter product revenues of $6.1 million, up 29.6% JERSEY, Channel Islands, ...
Quotient Limited (QTNT), a commercial-stage diagnostics company, today announced the appointment of Franz Walt, as its Chief Executive Officer. Mr Walt who retired earlier this year as the President of Siemens Healthineers, Laboratory Diagnostics, is a member of Quotient's Board of Directors, and had been appointed as the interim Chief Executive Officer recently in March.
Quotient Limited (QTNT), a commercial-stage diagnostics company, today reported that it has completed the verification and validation (V&V) phase for its initial blood grouping MosaiQ™ microarray (IH I) and has commenced its European field trials. “I am very pleased to announce the start of our European field trials for IH I. This is the next important step in our rigourous development process, that included the V&V performance data which we have previously shared.
JERSEY, Channel Islands, May 15, 2018-- Quotient Limited, a commercial-stage diagnostics company, today announced that financial results for its fourth quarter and fiscal full year ended March 31, 2018, ...
Understanding how Quotient Limited (NASDAQ:QTNT) is performing as a company requires looking at more than just a years’ earnings. Today I will run you through a basic sense check toRead More...
The Eysins, Jersey-based company said it had a loss of 47 cents per share. The blood test developer posted revenue of $5.9 million in the period. Quotient expects full-year revenue in the range of $24.1 ...